Medication Guide App

Label Changes for:

Firmagon (Degarelix for injection)

August 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

August 2013



  • The safety of Firmagon administered monthly was evaluated further in an extension study in 385 patients who completed the above active-controlled trial…


March 2013


Hypersensitivity Reactions
  • Hypersensitivity reactions, including anaphylaxis, urticaria and angioedema, have been reported post-marketing with Firmagon. In case of a serious hypersensitivity reaction, discontinue Firmagon immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of serious hypersensitivity reactions to Firmagon should not be re-challenged with Firmagon.